First publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Develops novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Has six FDA-approved therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD) and neuroblastoma. Working to create manufactured organs to address the shortage of transplantable organs.
